These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 11877767)

  • 1. High-dose myeloablative radioimmunotherapy of mantle cell non-Hodgkin lymphoma with the iodine-131-labeled chimeric anti-CD20 antibody C2B8 and autologous stem cell support. Results of a pilot study.
    Behr TM; Griesinger F; Riggert J; Gratz S; Béhé M; Kaufmann CC; Wörmann B; Brittinger G; Becker W
    Cancer; 2002 Feb; 94(4 Suppl):1363-72. PubMed ID: 11877767
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-dose [131I]tositumomab (anti-CD20) radioimmunotherapy and autologous hematopoietic stem-cell transplantation for adults > or = 60 years old with relapsed or refractory B-cell lymphoma.
    Gopal AK; Rajendran JG; Gooley TA; Pagel JM; Fisher DR; Petersdorf SH; Maloney DG; Eary JF; Appelbaum FR; Press OW
    J Clin Oncol; 2007 Apr; 25(11):1396-402. PubMed ID: 17312330
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Myeloablative anti-CD20 radioimmunotherapy +/- high-dose chemotherapy followed by autologous stem cell support for relapsed/refractory B-cell lymphoma results in excellent long-term survival.
    Wagner JY; Schwarz K; Schreiber S; Schmidt B; Wester HJ; Schwaiger M; Peschel C; von Schilling C; Scheidhauer K; Keller U
    Oncotarget; 2013 Jun; 4(6):899-910. PubMed ID: 23765188
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tandem high-dose therapy in relapsed and refractory B-cell lymphoma: results of a prospective phase II trial of myeloablative chemotherapy, followed by escalated radioimmunotherapy with (131)I-anti-CD20 antibody and stem cell rescue.
    Hohloch K; Sahlmann CO; Lakhani VJ; Wulf G; Glass B; Hasenkamp J; Meller J; Riggert J; Trümper L; Griesinger F
    Ann Hematol; 2011 Nov; 90(11):1307-15. PubMed ID: 21360108
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low- versus high-dose radioimmunotherapy with humanized anti-CD22 or chimeric anti-CD20 antibodies in a broad spectrum of B cell-associated malignancies.
    Behr TM; Wörmann B; Gramatzki M; Riggert J; Gratz S; Béhé M; Griesinger F; Sharkey RM; Kolb HJ; Hiddemann W; Goldenberg DM; Becker W
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3304s-3314s. PubMed ID: 10541379
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials.
    Wiseman GA; Kornmehl E; Leigh B; Erwin WD; Podoloff DA; Spies S; Sparks RB; Stabin MG; Witzig T; White CA
    J Nucl Med; 2003 Mar; 44(3):465-74. PubMed ID: 12621016
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue.
    Liu SY; Eary JF; Petersdorf SH; Martin PJ; Maloney DG; Appelbaum FR; Matthews DC; Bush SA; Durack LD; Fisher DR; Gooley TA; Bernstein ID; Press OW
    J Clin Oncol; 1998 Oct; 16(10):3270-8. PubMed ID: 9779701
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma: a multivariable cohort analysis.
    Gopal AK; Gooley TA; Maloney DG; Petersdorf SH; Eary JF; Rajendran JG; Bush SA; Durack LD; Golden J; Martin PJ; Matthews DC; Appelbaum FR; Bernstein ID; Press OW
    Blood; 2003 Oct; 102(7):2351-7. PubMed ID: 12750161
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of radiation dose estimation for myeloablative radioimmunotherapy for relapsed or recurrent mantle cell lymphoma using (131)I tositumomab to that of other types of non-Hodgkin's lymphoma.
    Rajendran J; Gopal A; Durack L; Fisher D; Press O; Eary J
    Cancer Biother Radiopharm; 2004 Dec; 19(6):738-45. PubMed ID: 15665621
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
    Plosker GL; Figgitt DP
    Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Iodine-131 rituximab radioimmunotherapy with BEAM conditioning and autologous stem cell transplant salvage therapy for relapsed/refractory aggressive non-Hodgkin lymphoma.
    Kruger PC; Cooney JP; Turner JH
    Cancer Biother Radiopharm; 2012 Nov; 27(9):552-60. PubMed ID: 23062193
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas.
    Vose JM; Wahl RL; Saleh M; Rohatiner AZ; Knox SJ; Radford JA; Zelenetz AD; Tidmarsh GF; Stagg RJ; Kaminski MS
    J Clin Oncol; 2000 Mar; 18(6):1316-23. PubMed ID: 10715303
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience.
    Kaminski MS; Estes J; Zasadny KR; Francis IR; Ross CW; Tuck M; Regan D; Fisher S; Gutierrez J; Kroll S; Stagg R; Tidmarsh G; Wahl RL
    Blood; 2000 Aug; 96(4):1259-66. PubMed ID: 10942366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma.
    Gopal AK; Rajendran JG; Petersdorf SH; Maloney DG; Eary JF; Wood BL; Gooley TA; Bush SA; Durack LD; Martin PJ; Matthews DC; Appelbaum FR; Bernstein ID; Press OW
    Blood; 2002 May; 99(9):3158-62. PubMed ID: 11964278
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pretargeted radioimmunotherapy (PRIT) for treatment of non-Hodgkin's lymphoma (NHL): initial phase I/II study results.
    Weiden PL; Breitz HB; Press O; Appelbaum JW; Bryan JK; Gaffigan S; Stone D; Axworthy D; Fisher D; Reno J
    Cancer Biother Radiopharm; 2000 Feb; 15(1):15-29. PubMed ID: 10740649
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radioimmunotherapy using 131I-rituximab in patients with advanced stage B-cell non-Hodgkin's lymphoma: initial experience.
    Bienert M; Reisinger I; Srock S; Humplik BI; Reim C; Kroessin T; Avril N; Pezzutto A; Munz DL
    Eur J Nucl Med Mol Imaging; 2005 Oct; 32(10):1225-33. PubMed ID: 15937686
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma.
    Maloney DG; Grillo-López AJ; White CA; Bodkin D; Schilder RJ; Neidhart JA; Janakiraman N; Foon KA; Liles TM; Dallaire BK; Wey K; Royston I; Davis T; Levy R
    Blood; 1997 Sep; 90(6):2188-95. PubMed ID: 9310469
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful treatment with a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) for a patient with relapsed mantle cell lymphoma who developed a human anti-chimeric antibody.
    Maeda T; Yamada Y; Tawara M; Yamasaki R; Yakata Y; Tsutsumi C; Onimaru Y; Kamihira S; Tomonaga M
    Int J Hematol; 2001 Jul; 74(1):70-5. PubMed ID: 11530808
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radioimmunotherapy of small-volume disease of metastatic colorectal cancer.
    Behr TM; Liersch T; Greiner-Bechert L; Griesinger F; Béhé M; Markus PM; Gratz S; Angerstein C; Brittinger G; Becker H; Goldenberg DM; Becker W
    Cancer; 2002 Feb; 94(4 Suppl):1373-81. PubMed ID: 11877768
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Myeloablative I-131-tositumomab with escalating doses of fludarabine and autologous hematopoietic transplantation for adults age ≥ 60 years with B cell lymphoma.
    Gopal AK; Gooley TA; Rajendran JG; Pagel JM; Fisher DR; Maloney DG; Appelbaum FR; Cassaday RD; Shields A; Press OW
    Biol Blood Marrow Transplant; 2014 Jun; 20(6):770-5. PubMed ID: 24530971
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.